Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo C49 English + 你好 (nǐ hǎo) = limitless possibilities. Start learning Mandarin Chinese today—for free, forever. Amedeo C49 is completely free, for life. Next week: +49.

Liver Diseases

Free Subscription Articles published in Oncogene Retrieve available abstracts of 54 articles: HTML format

Single Articles

October 2025
1. TSUCHIYA H, Hanaki T, Sakabe T, Tokuyasu N, et al
   Immune evasion from macrophages by NEAT1-induced CD24 in liver cancer.
   Oncogene. 2025;44:3652-3664.
   PubMed     Abstract available
   
   
   September 2025
2. LI J, Mao S, Yang S, Lou Y, et al
   Targeting JMJD6/PPARgamma/GPX4 axis overcomes ferroptosis resistance and enhances therapeutic efficacy in hepatocellular carcinoma.
   Oncogene. 2025 Sep 30. doi: 10.1038/s41388-025-03581.
   PubMed     Abstract available
   
   
   
3. WU Z, Duan W, Xiong Y, Liu J, et al
   Publisher Correction: NeuroD1 drives a KAT2A-FDFT1 signaling axis to promote cholesterol biosynthesis and hepatocellular carcinoma progression via histone H3K27 acetylation.
   Oncogene. 2025 Sep 22. doi: 10.1038/s41388-025-03574.
   PubMed    
   
   
   
4. ZHAO J, Cui M, Yao X, Jiang Z, et al
   Targeting TFAM downregulation mediated mtDNA-NLRP3 pathway suppresses TAM infiltration and HCC progression.
   Oncogene. 2025;44:2956-2969.
   PubMed     Abstract available
   
   
   
5. WU Z, Duan W, Xiong Y, Liu J, et al
   NeuroD1 drives a KAT2A-FDFT1 signaling axis to promote cholesterol biosynthesis and hepatocellular carcinoma progression via histone H3K27 acetylation.
   Oncogene. 2025 Sep 1. doi: 10.1038/s41388-025-03534.
   PubMed     Abstract available
   
   
   August 2025
6. SUN C, Cai S, Yang J, Du M, et al
   OTUB1 antagonizes TRIM21 to induce deubiquitination of SPHK1 and promote the progression of hepatocellular carcinoma.
   Oncogene. 2025 Aug 30. doi: 10.1038/s41388-025-03556.
   PubMed     Abstract available
   
   
   
7. HAN H, Gong C, Zhang Y, Liu C, et al
   RBM30 recruits DOT1L to activate STAT1 transcription and drive immune evasion in hepatocellular carcinoma.
   Oncogene. 2025 Aug 29. doi: 10.1038/s41388-025-03550.
   PubMed     Abstract available
   
   
   
8. HAN J, Wang F, Lan Y, Wang J, et al
   Retraction Note to: KIFC1 regulated by miR-532-3p promotes epithelial-to-mesenchymal transition and metastasis of hepatocellular carcinoma via gankyrin/AKT signaling.
   Oncogene. 2025 Aug 11. doi: 10.1038/s41388-025-03527.
   PubMed    
   
   
   July 2025
9. GUO S, Zhang Q, Ma J, Zou Y, et al
   PABPN1-C5 axis promotes hepatocellular carcinoma progression via NF-kappaB activation.
   Oncogene. 2025 Jul 28. doi: 10.1038/s41388-025-03501.
   PubMed     Abstract available
   
   
   May 2025
10. GENG X, Li M, Zhang L, Cai Y, et al
    P5CS deacetylation mediated by SIRT2 facilitates tumor growth by enhancing mitochondrial respiration in hepatocellular carcinoma.
    Oncogene. 2025 May 27. doi: 10.1038/s41388-025-03456.
    PubMed     Abstract available
    
    
    
11. SOUDAH N, Baskin A, Darash-Yahana M, Darlyuk-Saadon I, et al
    Erk1(R84H) is an oncoprotein that causes hepatocellular carcinoma in mice and imposes a rigorous negative feedback loop.
    Oncogene. 2025 May 20. doi: 10.1038/s41388-025-03437.
    PubMed     Abstract available
    
    
    
12. DENG L, Tang J, Yang H, Cheng C, et al
    Retraction Note: MTA1 modulated by miR-30e contributes to epithelial-to-mesenchymal transition in hepatocellular carcinoma through an ErbB2-dependent pathway.
    Oncogene. 2025 May 12. doi: 10.1038/s41388-025-03433.
    PubMed    
    
    
    
13. SHU Y, Tao Q, Xu Q, Chen Y, et al
    Loss of NUMB promotes hepatomegaly and hepatocellular carcinoma through the AKT/glycogen/hippo signaling.
    Oncogene. 2025 May 3. doi: 10.1038/s41388-025-03430.
    PubMed     Abstract available
    
    
    
14. SHA N, Zhou B, Hou G, Xi Z, et al
    The protection of UCK2 protein stability by GART maintains pyrimidine salvage synthesis for HCC growth under glucose limitation.
    Oncogene. 2025;44:1078-1092.
    PubMed     Abstract available
    
    
    April 2025
15. HU H, Zhan X, Xiong Y, Yuan R, et al
    Non-classic deubiquitinase USP13 inhibits bladder cancer metastasis through destabilizing cytoplasmic KDM3A.
    Oncogene. 2025 Apr 19. doi: 10.1038/s41388-025-03410.
    PubMed     Abstract available
    
    
    
16. ZHANG H, Kong X, Qu H, Gao Y, et al
    MYCBP2-mediated HNF4alpha ubiquitination reprogrammed lipid metabolism in MASH-associated hepatocellular carcinoma.
    Oncogene. 2025 Apr 3. doi: 10.1038/s41388-025-03373.
    PubMed     Abstract available
    
    
    
17. LI D, Gao Z, Zhang Z, Chen H, et al
    Suprabasin promotes gastric cancer liver metastasis via hepatic stellate cells-mediated EGF/CCL2/JAK2 intercellular signaling pathways.
    Oncogene. 2025 Apr 3. doi: 10.1038/s41388-025-03370.
    PubMed     Abstract available
    
    
    
18. ZHANG GP, Song ZB, Chen DH, Yu Y, et al
    Syntaxin-6 mediated autophagy confers lenvatinib resistance in hepatocellular carcinoma.
    Oncogene. 2025 Apr 3. doi: 10.1038/s41388-025-03371.
    PubMed     Abstract available
    
    
    
19. LU Y, Li X, Liu H, Xue J, et al
    Retraction Note: beta-Trcp and CK1delta-mediated degradation of LZTS2 activates PI3K/AKT signaling to drive tumorigenesis and metastasis in hepatocellular carcinoma.
    Oncogene. 2025;44:931.
    PubMed    
    
    
    March 2025
20. JIANG S, Jiang L, Xu Y, Ma Y, et al
    USP5 deubiquitinates and stabilizes IMPDH2, to promote hepatocellular carcinoma progression.
    Oncogene. 2025 Mar 31. doi: 10.1038/s41388-025-03355.
    PubMed     Abstract available
    
    
    
21. ZHOU J, Wang J, Yang L, Fu T, et al
    N6-methyadenosine-modified YWHAE mRNA promotes proliferation and inhibits ferroptosis in hepatoblastoma by mediating SLC7A11 expression.
    Oncogene. 2025 Mar 12. doi: 10.1038/s41388-025-03334.
    PubMed     Abstract available
    
    
    
22. ZHU J, Wang L, Nie X, Ou S, et al
    RBMS3-loss impedes TRIM21-induced ubiquitination of ANGPT2 in an RNA-independent manner and drives sorafenib resistance in hepatocellular carcinoma.
    Oncogene. 2025 Mar 11. doi: 10.1038/s41388-025-03335.
    PubMed     Abstract available
    
    
    
23. LIANG Y, Qiao L, Qian Q, Zhang R, et al
    Integrated single-cell and spatial transcriptomic profiling reveals that CD177(+) Tregs enhance immunosuppression through apoptosis and resistance to immunotherapy in hepatocellular carcinoma.
    Oncogene. 2025 Mar 7. doi: 10.1038/s41388-025-03330.
    PubMed     Abstract available
    
    
    
24. ZHANG B, Zhou Y, Xu X, Xu G, et al
    RBM39 promotes hepatocarcinogenesis by regulating RFX1's alternative splicing and subsequent activation of integrin signaling pathway.
    Oncogene. 2025 Mar 3. doi: 10.1038/s41388-025-03327.
    PubMed     Abstract available
    
    
    
25. XU J, Li Y, Wang G, Chen D, et al
    Impaired mitochondrial degradation of CHCHD2 promotes metabolic dysfunction-associated steatohepatitis-related hepatocellular carcinoma by upregulating VEGFA.
    Oncogene. 2025 Mar 1. doi: 10.1038/s41388-025-03321.
    PubMed     Abstract available
    
    
    February 2025
26. LI Y, Ouyang Q, Chen Z, Zhou D, et al
    Novel role of general transcript factor IIH subunit 2 (GTF2H2) in the development and sex disparity of hepatocellular carcinoma.
    Oncogene. 2025 Feb 19. doi: 10.1038/s41388-025-03301.
    PubMed     Abstract available
    
    
    November 2024
27. ZHUANG M, Liu J, Li Y, Zhang J, et al
    PD-L1 promotes tumor metastasis by regulating the infiltration of FGFBP2(+)Tm cells in colorectal cancer.
    Oncogene. 2024 Nov 18. doi: 10.1038/s41388-024-03223.
    PubMed     Abstract available
    
    
    October 2024
28. XING H, Gu X, Liu Y, Xu L, et al
    NSUN2 regulates Wnt signaling pathway depending on the m5C RNA modification to promote the progression of hepatocellular carcinoma.
    Oncogene. 2024 Oct 7. doi: 10.1038/s41388-024-03184.
    PubMed     Abstract available
    
    
    
29. LI X, Hu Z, Shi Q, Qiu W, et al
    Elevated choline drives KLF5-dominated transcriptional reprogramming to facilitate liver cancer progression.
    Oncogene. 2024;43:3121-3136.
    PubMed     Abstract available
    
    
    
30. LIU Z, Hu Q, Luo Q, Zhang G, et al
    NUP37 accumulation mediated by TRIM28 enhances lipid synthesis to accelerate HCC progression.
    Oncogene. 2024;43:3255-3267.
    PubMed     Abstract available
    
    
    September 2024
31. XIE P, Wu M, Wang H, Zhang B, et al
    GOLM1 dictates acquired Lenvatinib resistance by a GOLM1-CSN5 positive feedback loop upon EGFR signaling activation in hepatocellular carcinoma.
    Oncogene. 2024 Sep 9. doi: 10.1038/s41388-024-03153.
    PubMed     Abstract available
    
    
    
32. DU J, Bai D, Gu C, Zhao J, et al
    Sorafenib-mediated cleavage of p62 initiates cellular senescence as a mechanism to evade its anti-hepatocellular carcinoma efficacy.
    Oncogene. 2024 Sep 4. doi: 10.1038/s41388-024-03142.
    PubMed     Abstract available
    
    
    August 2024
33. HAN H, Shi Q, Zhang Y, Ding M, et al
    RBM12 drives PD-L1-mediated immune evasion in hepatocellular carcinoma by increasing JAK1 mRNA translation.
    Oncogene. 2024 Aug 26. doi: 10.1038/s41388-024-03140.
    PubMed     Abstract available
    
    
    
34. CUI M, Liu Z, Wang S, Bae S, et al
    CRISPR-based dissection of microRNA-23a ~ 27a ~ 24-2 cluster functionality in hepatocellular carcinoma.
    Oncogene. 2024 Aug 7. doi: 10.1038/s41388-024-03115.
    PubMed     Abstract available
    
    
    
35. TANG X, Gao L, Jiang X, Hou Z, et al
    Single-cell profiling reveals altered immune landscape and impaired NK cell function in gastric cancer liver metastasis.
    Oncogene. 2024;43:2635-2646.
    PubMed     Abstract available
    
    
    July 2024
36. ZHANG T, Zhao F, Hu Y, Wei J, et al
    Environmental monobutyl phthalate exposure promotes liver cancer via reprogrammed cholesterol metabolism and activation of the IRE1alpha-XBP1s pathway.
    Oncogene. 2024;43:2355-2370.
    PubMed     Abstract available
    
    
    
37. LI W, Guo Z, Zhou Z, Zhou Z, et al
    Distinguishing high-metastasis-potential circulating tumor cells through fluidic shear stress in a bloodstream-like microfluidic circulatory system.
    Oncogene. 2024;43:2295-2306.
    PubMed     Abstract available
    
    
    June 2024
38. GU J, Xu X, Li X, Yue L, et al
    Tumor-resident microbiota contributes to colorectal cancer liver metastasis by lactylation and immune modulation.
    Oncogene. 2024 Jun 18. doi: 10.1038/s41388-024-03080.
    PubMed     Abstract available
    
    
    
39. KE R, Viswakarma N, Menhart M, Singh SK, et al
    MLK3 promotes prooncogenic signaling in hepatocellular carcinoma via TGFbeta pathway.
    Oncogene. 2024 Jun 10. doi: 10.1038/s41388-024-03055.
    PubMed     Abstract available
    
    
    
40. LI X, He W, Chen X, Zhang Y, et al
    TRIM45 facilitates NASH-progressed HCC by promoting fatty acid synthesis via catalyzing FABP5 ubiquitylation.
    Oncogene. 2024;43:2063-2077.
    PubMed     Abstract available
    
    
    March 2024
41. DENG T, Zhao J, Tong Y, Chen Z, et al
    Crosstalk between endothelial progenitor cells and HCC through periostin/CCL2/CD36 supports formation of the pro-metastatic microenvironment in HCC.
    Oncogene. 2024;43:944-961.
    PubMed     Abstract available
    
    
    February 2024
42. ZHANG T, Zhao F, Zhang Y, Shi JH, et al
    Targeting the IRE1alpha-XBP1s axis confers selective vulnerability in hepatocellular carcinoma with activated Wnt signaling.
    Oncogene. 2024 Feb 28. doi: 10.1038/s41388-024-02988.
    PubMed     Abstract available
    
    
    
43. FENG Z, Yin J, Zhang Z, Chen Z, et al
    O-GlcNAcylation of E3 ubiquitin ligase SKP2 promotes hepatocellular carcinoma proliferation.
    Oncogene. 2024 Feb 23. doi: 10.1038/s41388-024-02977.
    PubMed     Abstract available
    
    
    
44. LI B, Xiong X, Xu J, Peng D, et al
    METTL3-mediated m(6)A modification of lncRNA TSPAN12 promotes metastasis of hepatocellular carcinoma through SENP1-depentent deSUMOylation of EIF3I.
    Oncogene. 2024 Feb 19. doi: 10.1038/s41388-024-02970.
    PubMed     Abstract available
    
    
    January 2024
45. GENG L, Zhu M, Luo D, Chen H, et al
    TKT-PARP1 axis induces radioresistance by promoting DNA double-strand break repair in hepatocellular carcinoma.
    Oncogene. 2024 Jan 12. doi: 10.1038/s41388-023-02935.
    PubMed     Abstract available
    
    
    
46. GU X, Li P, Gao X, Ru Y, et al
    RNA 5-methylcytosine writer NSUN5 promotes hepatocellular carcinoma cell proliferation via a ZBED3-dependent mechanism.
    Oncogene. 2024 Jan 5. doi: 10.1038/s41388-023-02931.
    PubMed     Abstract available
    
    
    December 2023
47. WANG C, Chen Z, Yi Y, Ding Y, et al
    RBM45 reprograms lipid metabolism promoting hepatocellular carcinoma via Rictor and ACSL1/ACSL4.
    Oncogene. 2023 Dec 1. doi: 10.1038/s41388-023-02902.
    PubMed     Abstract available
    
    
    November 2023
48. CAO K, Wang R, Li L, Liao Y, et al
    Targeting DDX11 promotes PARP inhibitor sensitivity in hepatocellular carcinoma by attenuating BRCA2-RAD51 mediated homologous recombination.
    Oncogene. 2023 Nov 25. doi: 10.1038/s41388-023-02898.
    PubMed     Abstract available
    
    
    
49. CHEN J, Ning D, Du P, Liu Q, et al
    USP11 potentiates HGF/AKT signaling and drives metastasis in hepatocellular carcinoma.
    Oncogene. 2023 Nov 16. doi: 10.1038/s41388-023-02847.
    PubMed     Abstract available
    
    
    
50. LIU F, Liao Z, Zhang Z
    MYC in liver cancer: mechanisms and targeted therapy opportunities.
    Oncogene. 2023;42:3303-3318.
    PubMed     Abstract available
    
    
    September 2023
51. ZHOU J, Xu W, Wu Y, Wang M, et al
    GPR37 promotes colorectal cancer liver metastases by enhancing the glycolysis and histone lactylation via Hippo pathway.
    Oncogene. 2023 Sep 25. doi: 10.1038/s41388-023-02841.
    PubMed     Abstract available
    
    
    
52. YU A, Yu P, Zhu Y, Zhu R, et al
    Glucose-induced and ChREBP: MLX-mediated lipogenic program promotes hepatocellular carcinoma development.
    Oncogene. 2023 Sep 9. doi: 10.1038/s41388-023-02831.
    PubMed     Abstract available
    
    
    
53. DU D, Qin M, Shi L, Liu C, et al
    RNA binding motif protein 45-mediated phosphorylation enhances protein stability of ASCT2 to promote hepatocellular carcinoma progression.
    Oncogene. 2023 Sep 1. doi: 10.1038/s41388-023-02795.
    PubMed     Abstract available
    
    
    
54. QIAO X, Lin J, Shen J, Chen Y, et al
    FBXO28 suppresses liver cancer invasion and metastasis by promoting PKA-dependent SNAI2 degradation.
    Oncogene. 2023;42:2878-2891.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Liver Diseases is free of charge.